Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Gene Therapy - Worldwide Market Challenges' returned 239 results - Page 1 of 12   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 345 of neurological disorders will be biological therapies and these will require innovative methods for delivery. Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also Personalized Medicine - Scientific and Commercial Aspects   Jain PharmaBiotech, May 2012, Pages: 798 and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient's cells in vitro, prior to reimplantation of these cells in the patient's body. Various technologies are integrated RNAi - Technologies, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 485 RNAs in acute coronary syndrome miRNA-based approaches for reduction of hypercholesterolemia miRNA-based approach for restenosis following angioplasty miRNA gene therapy for ischemic heart disease mi Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders   GlobalData, April 2012, Pages: 4 cell anemia - Challenges to Gene Therapy - Market Implications Reasons to buy - Understand the effectiveness of gene therapy in the treatment of red blood cell disorders - Get the most up to date gene Neuroprotection - Drugs, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 633 agents, neurotrophic factors, metal ion chelators, ion channel modulators and gene therapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products Nanobiotechnology Applications, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 754 , nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology Alzheimer Disease - New Drugs, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 534 cognition in AD via BDNF Drugs for enhancing neuronal differentiation of implanted NSCs Implantation of encapsulated cells for delivering NGF Gene therapy for AD ApoE gene therapy FGF2 gene transfer Molecular Diagnostics - Technologies, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 1037 diagnosis in the design of future cancer therapies Molecular classification of cancer Determination of cancer prognosis Prognosis by tumor classification Prognosis by cancer gene expression Selection Biomarkers - Technologies, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 873 as biomarker of efficacy of cancer gene therapy Biomarkers of angiogenesis for developing antiangiogenic therapy Biomarkers of response to antiangiogenic agents Circulating endothelial cells as targets Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities   PharmaVision, July 2009, Pages: 225 the 1990s scientists across the world have begun to harness the power of RNA interference (RNAi) to silence genes in a multitude of diseases. However, many challenges face those aiming to develop RNAi-based Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships   Espicom Business Intelligence Ltd, Sep 2011, Pages: 188 pharmacokinetics of approved and new compounds, as well as the emergence of novel biologics, nucleic acidbased medicines and small molecule agents. BIOVECTORS/GENE THERAPY/VACCINES During the last twenty years DNA Sequencing - Technologies, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 309 , gene therapy and biopharmaceuticals. Challenges in Delivery of Therapeutic Genomics and Proteomics   Elsevier Science and Technology, Sep 2010, Pages: 686 - Challenges and Opportunities 3. Physical Methods of Gene Delivery 4. Gene Delivery Using Chemical Methods 5. Gene Delivery Using Viral Vectors 6. Applications of Gene Therapy 7. Antisense Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies   GBI Research, Feb 2011, Pages: 209 Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies This report provides an in-depth analysis of the unmet needs, drivers Does the Treatment of Huntington's Disease Represent a Commercial Opportunity?   Decision Resources, Inc., Aug 2007, Pages: 22 ). -Novel treatment approaches: stem-cell transplantation and gene therapy. -Challenges and outlook: the future of the HD market. Executive Summary Strategic Considerations Stakeholder Implications Lipid Nanocarriers in Cancer Diagnosis and Therapy   Smithers Information Ltd, Aug 2011, Pages: 557 nanocarriers are also used for gene therapy for cancer. Also addressed is how diagnostic strategies with lipid nanocarriers can be combined with therapeutics, which will be important for the personalized Advancing Molecular Diagnostics to Personalize Cancer Therapy   Business Insights, June 2011, Pages: 187 testing Microfluidics Gene expression profiling Variety The role of biomarkers Prognostic Predictive Evaluating therapeutic activity Challenges and issues Commercializing theranostics Regulatory Proteomics - Technologies, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 617 therapeutics Peptide-based drugs Phylomer® peptides Cryptein-based therapeutics Synthetic proteins and peptides as pharmaceuticals Genetic immunization and proteomics Proteomics and gene therapy Role World Gene Therapy Market   Frost & Sullivan, May 2005 of this research. The market faces major challenges in patient recruitment and in the improvement of clinical success, but if these are overcome, the results will herald a new era of medicine. First Gene Therapy Products Approach RNA Therapy: The Next Big Thing after Monoclonal Antibodies?   Datamonitor, Oct 2008, Pages: 80 potential targets 21 Gene therapy also offers significant potential, but has fallen out of favour 21 History/ discovery 23 Antisense silencing 23 Antisense technology has been available for over 30 years 23 Results:  First -   Prev -   1 -   2 -   3 -   4 -   5 -   6 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets2    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network